However, some data shows that this group of HLA proteins may be predominantly responsible for the sensitivity of melanoma cells to anti-CTLA-4 treatment, while the expression of HLA class II molecules predicts response to anti-PD-1 therapy [41]. Here, PDCD1 is linked to melanoma.